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Design.-In September 2010, a questionnaire was distributed by the College of American Pathologists. It was composed of 32 questions relating to nonpredictive assays as well as non-US Food and Drug Administration (non-FDA)-approved, predictive IHC assays other than human epidermal growth factor 2 (HER2/neu).
Results.-For non-FDA approved, nonpredictive IHC assays, 68% of laboratories had a written validation procedure. Eighty-six percent of laboratories validated the most recently introduced nonpredictive antibody. Seventy-five percent used 21 or fewer total cases for the validation and 40% used weakly or focally positive cases. Forty-six percent of respondents had a written procedure for validation procedures for non-FDA approved, predictive marker IHC assays other than HER2/neu. Seventy-five percent of laboratories validated the most recently introduced predictive antibody other than HER2/neu. Fewer than half used 25 or more cases for the validation, and 47% used weakly or focally positive cases.
Conclusion.-Some laboratories have written validation procedures that appear to build upon HER2/neu testing guidelines. Some laboratories also manage to validate new antibodies according to those standards; however, many do not. There appears to be a need for further validation guideline development for nonpredictive and non-FDA approved predictive antibody IHC assays.
(Arch Pathol Lab Med. 2013;137:19-25; doi: 10.5858/ arpa.2011-0676-CP) I n recent years, immunohistochemical (IHC) assays have been rapidly and prolifically incorporated into everyday surgical pathology. While other areas of the laboratory have detailed requirements for diagnostic performance, IHC staining poses unique challenges that have left it without broadly implemented practice standards. In 1998, the US Food and Drug Administration (FDA) classified IHC antibodies as ''analyte-specific reagents.'' 1 Within this defined group, most antibodies are deemed ''Class I'' medical devices, exempting them from premarket FDA notification, which entails providing evidence of safety and efficacy. A few IHC markers, including estrogen and progesterone receptors, are ''Class II'' medical devices, meaning they have associated guidance documents. The rationale behind Class I categorization is that IHC results are just one part of the final diagnostic interpretation by the pathologist. The flexibility provided by such a designation can be credited with rapid development of new antibodies. Unfortunately, it lends itself to divergent practices and inconsistent results among laboratories. There is a strong body of literature detailing the unique challenges to validating IHC assays, but the field is still short of a clearly defined standard. Clinical Laboratory Standards Institute (CLSI) guidelines require that individual laboratories validate each new antibody; however, the details are left to the laboratory director.
Predictive markers, such as human epidermal growth factor 2 (HER2/neu), whose results bear prognostic and treatment implications, have been the first targets of enhanced standardization. In December 2006, the American Society of Clinical Oncology and the College of American Pathologists (CAP) introduced guidelines for HER2/neu testing, which were published in January 2007. 2 These guidelines came in response to studies indicating that up to 20% of HER2/neu results may be discordant with another laboratory. 3, 4 It was anticipated that the new guidelines would improve test accuracy and patient safety. This hypothesis was tested by way of a supplemental questionnaire, distributed by CAP in late 2008 and published in May 2010. 5 The study revealed that while some of the guidelines had been implemented, gaps remained. For example, of the laboratories comparing IHC HER2/neu assays with an IHC test performed in another laboratory, only 56% of laboratories used a recommended minimum of 25 cases. Additional measures toward enhanced quality include guidelines for validation of hormone receptor assays (2010). The path toward consistently accurate IHC results is far from complete, yet it becomes increasingly important as pressure mounts to achieve personalized treatment and as the collection of predictive markers grows. A major initial step for laboratories is to achieve uniformity in antibody validation. The purpose of the current study was to understand current practices and the extent of IHC validation procedures that currently exist in order to determine where laboratories may benefit from standardized guidelines for IHC validation.
MATERIALS AND METHODS
In September 2010, participants were mailed the Immunohistochemistry Validation Practices and Procedures Questionnaire alongside the HER2-B Immunohistochemistry, Tissue Microarray Survey Result Form. Of the 1064 HER2-B surveys distributed, 1008 were returned, and of these, the questionnaire was returned by 754 participants. For cases in which the survey skip sequence was not followed, question responses were set to ''missing.'' Data were also excluded from 27 laboratories that submitted only 1 page of the questionnaire, such that the final summary is based on 727 respondents.
The questionnaire was composed of 32 items; most had predetermined, multiple-choice answers; some required a numerical response. Fourteen questions focused on non-FDAapproved, nonpredictive IHC assays. Thirteen questions focused on non-FDA-approved, predictive IHC assays other than HER2/ neu. Four questions were related to all IHC assays in use and 1 to case volume (total surgical pathology accessions).
Results were analyzed to determine if practice characteristics varied by the total number of 2009 surgical pathology accessions and by the total number of antibodies used in the IHC laboratory. Individual associations between the 2 volumes and the practice characteristics were investigated with Kruskal-Wallis tests for categorical variables and least squares regression for the continuous variables.
For presentation purposes, the continuous variables were discretized, but the P values are based on the least squares regression analysis.
A significance level of .05 was used for the analysis. The data were summarized and analyzed with SAS 9.2 (Cary, North Carolina). Table 1 demonstrates the laboratory size distributions with respect to number of antibodies in use, number of new antibodies introduced in 2009, and number of surgical pathology accessions. Tables 2 and 3 show the extent of written validation procedures for all non-FDA-approved, nonpredictive IHC assays. Sixty-eight percent of respondents had a written validation procedure. Laboratories reported a median of 13 cases for IHC validation with a target of 95% concordance. Tables 4, 5 , and 6 show data regarding validation procedures of respondents' most recently introduced non-FDA-approved, nonpredictive IHC assays. Eighty-six percent of respondents had validated the most recently introduced antibody, with a median of 11 total cases. Fiftythree percent had run the validation on multiple days to assess between-run precision. Tables 7 and 8 demonstrate the extent of written validation procedures for non-FDA-approved, predictive marker IHC assays other than HER2/neu. Forty-six percent of respondents had a written validation procedure for non-FDA-approved, predictive marker IHC assays. Laboratories designated a median of 25 total cases for validation with an expectation of 95% concordance. Tables 9 and 10 show data about validation procedures of their most recently introduced non-FDA-approved, predictive IHC assay for clinical use. Table 9 shows some of the antibodies most recently introduced. The numbers of cases used during the validation procedure are shown in Table 10 . Seventy-five percent of respondents had validated the most recently introduced antibody, with a median of 15 total cases. Table 11 shows the extent of written procedures to repeat validation procedures and ongoing assay assessment.
RESULTS

COMMENT
One of the primary objectives of this study was to understand existing laboratory practices regarding IHC validation procedures. We are able to describe these practices with broad study participation of 727 laboratories and an annual number of surgical accessions ranging from 5227 to 55 000 at the 10th and 90th percentiles. The survey as a whole highlighted some particular issues for IHC validation. For predictive and nonpredictive antibodies, laboratories performed validation at a higher rate (75% and 86%) than the availability of written procedures (46% and 68%). When the data were restricted to laboratories with a current procedure, most were able to meet the minimum designated cases (Tables 6 and 10) , although there was a trend toward using slightly fewer cases. The factors contributing to this trend are not entirely clear; however, it is likely that tissue availability and laboratory size prohibit more extensive testing. The data also show that smaller laboratories had a trend toward use of fewer cases than larger laboratories; however, this was not statistically significant (Tables 3, 6 , 8, and 10). CLSI has stated that an average laboratory may not be capable of validating many of the antibodies in use, particularly predictive antibodies; however, our data show that most laboratories are at least able to meet the currently designated minimum. Some may feel these minimums are too low, but enforcing more extensive testing should only come with supporting evidence. Most laboratories operate under strict cost constraints and the need to justify the expense of extensive testing may explain some of our results. The availability of appropriate tissue controls is also an issue, but it is highly dependent upon the particular antibody used. Even when ample tissue is available, it is a timely pursuit to identify cases.
Scarce tissue poses a particular challenge in validation of cytologic material, which could explain why only 37% to 42% of written procedures made specific mention of cytologic material. Another problematic area involves weakly or focally positive cases, which may be more difficult to obtain or identify. Smaller laboratories were less likely to have used such cases in the most recent validation (P 5 .005, Table 5 ), and fewer than 50% of all respondents used weakly or focally positive cases in the most recent validation; however, inclusion of such cases may not be applicable to all antibodies. One shortcoming of this survey is that a definition of weak or focally positive cases was not given.
Interestingly, while much has been written about the need to achieve quality validation procedures, few have ventured to suggest a minimum number of cases to accomplish that goal. This is understandable, since doing so has tremendous consequences. A number too low could give pathologists a degree of false confidence in stain performance, and a number too high is costly and timeconsuming and could make it impossible for smaller laboratories to perform IHC on site. Our study provides no evidence to support any specific minimum number of cases. It is worth noting, however, that most respondents felt a minimum of 25 cases was appropriate for validation of a predictive marker and 13 cases for nonpredictive markers. There also appears to be consensus that a more thorough validation process is warranted for predictive markers. These practice characteristics may be a result of greater scrutiny of predictive tests such as HER2/neu, as well as the HER2/neu guideline-suggested minimum of 25 cases. Another reason is that predictive markers are much less likely to have morphologic clues to refute an errant stain.
One of our objectives was to gain an understanding of laboratory revalidation practices. Tables 2 and 7 demonstrate selected aspects of validation procedures and the specific triggers for repeating the validation. We were surprised that only 66% and 64% of predictive and nonpredictive procedures, respectively, required repeated assay validation after introduction of a new antibody. We realize that there may have been confusion owing to use of the term validate rather than verify. The FDA defines validation as ''confirmation by examination and provision of objective evidence that the particular requirements for a specific intended use can be consistently fulfilled.'' 8, 9 It defines verification as ''a study used to determine whether a test system meets specifications.'' 8-10 CLSI defines verification as ''a one-time process completed to determine or confirm test performance characteristics before the test system is used for patient testing.'' 11 Our survey question used the term validation when verification is more appropriate; this likely deflated the result. If we use consensus opinion as a benchmark of quality for validation procedures, the data show that most procedures require repeated validation for preanalytic variables, such as a change in fixative or tissue processor, and for analytic variables, such as a change in detection system, antigen retrieval, or instrumentation. We infer that most respondents felt such elements were necessary.
As a cautionary note, of the 1064 surveys that were sent out, only 68% were completed. While this is a relatively high rate of return, the data should be interpreted with caution owing to any potential self-selection bias. Also, no instruction was given as to whom should complete the survey. It is presumed that the survey was filled out by either the laboratory director or the laboratory manager or both, but this is unknown.
In summary, we report our survey findings from 727 laboratories, demonstrating the current state of IHC validation. Some laboratories have written validation procedures that appear to build upon HER2/neu testing guidelines. Many laboratories also manage to validate new antibodies according to those standards. As the field of immunohistochemistry matures and as clinical teams increasingly seek to base decisions upon a single antibody result, the laboratory must make every effort to optimize the quality of its results. Development and implementation of thoughtful validation procedures is an essential component in that process. The publication of a practice guideline in this area should be beneficial in reducing current gaps in performance. 
